Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 284 articles:
HTML format
Text format



Single Articles


    September 2018
  1. XU R, Zhu J
    Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Sep 7. pii: S0169-5002(18)30559.
    PubMed     Text format    


  2. GARON EB, Siegfried JM, Stabile LP, Young PA, et al
    Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
    Lung Cancer. 2018;123:91-98.
    PubMed     Text format     Abstract available


  3. SCILLA KA, Zandberg DP, Bentzen SM, Mainor C, et al
    Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Lung Cancer. 2018;123:87-90.
    PubMed     Text format     Abstract available


  4. VUONG HG, Ho ATN, Altibi AMA, Nakazawa T, et al
    Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Lung Cancer. 2018;123:76-82.
    PubMed     Text format     Abstract available


  5. JIAO XD, Qin BD, You P, Cai J, et al
    The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Lung Cancer. 2018;123:70-75.
    PubMed     Text format     Abstract available


  6. SONG Y, Zhou Q, Zhang X, Chen GY, et al
    Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
    Lung Cancer. 2018;123:7-13.
    PubMed     Text format     Abstract available


  7. SUH CH, Park HS, Kim KW, Pyo J, et al
    Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018;123:60-69.
    PubMed     Text format     Abstract available


  8. LU S, Kong H, Hou Y, Ge D, et al
    Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer.
    Lung Cancer. 2018;123:44-51.
    PubMed     Text format     Abstract available


  9. LIU F, Liu Y, Liu X, Mao K, et al
    Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Lung Cancer. 2018;123:36-43.
    PubMed     Text format     Abstract available


  10. TAIRA N, Atsumi E, Nakachi S, Takamatsu R, et al
    Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the (18)F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.
    Lung Cancer. 2018;123:30-35.
    PubMed     Text format     Abstract available


  11. JAO K, Tomasini P, Kamel-Reid S, Korpanty GJ, et al
    The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Lung Cancer. 2018;123:22-29.
    PubMed     Text format     Abstract available


  12. HU X, Hay JW
    First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Lung Cancer. 2018;123:166-171.
    PubMed     Text format     Abstract available


  13. STEWART I, Khakwani A, Hubbard RB, Beckett P, et al
    Are working practices of lung cancer nurse specialists associated with variation in peoples' receipt of anticancer therapy?
    Lung Cancer. 2018;123:160-165.
    PubMed     Text format     Abstract available


  14. CARDINALE D, Cosentino N, Moltrasio M, Sandri MT, et al
    Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide.
    Lung Cancer. 2018;123:155-159.
    PubMed     Text format     Abstract available


  15. POMPILI C, Koller M, Velikova G, Franks K, et al
    EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).
    Lung Cancer. 2018;123:149-154.
    PubMed     Text format     Abstract available


  16. CHO BC, Dy GK, Govindan R, Kim DW, et al
    Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
    Lung Cancer. 2018;123:14-21.
    PubMed     Text format     Abstract available


  17. FINKLE JH, Penney BC, Pu Y
    An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Lung Cancer. 2018;123:136-141.
    PubMed     Text format     Abstract available


  18. LI Z, Maeda D, Yoshida M, Umakoshi M, et al
    The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Lung Cancer. 2018;123:127-135.
    PubMed     Text format     Abstract available


  19. KOUL R, Rathod S, Dubey A, Bashir B, et al
    Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Lung Cancer. 2018;123:116-120.
    PubMed     Text format     Abstract available


  20. DE JONG EEC, Hendriks LEL, van Elmpt W, Gietema HA, et al
    What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.
    Lung Cancer. 2018;123:112-115.
    PubMed     Text format     Abstract available


  21. HASHIMOTO K, Daddi N, Giuliani M, Hope A, et al
    The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer.
    Lung Cancer. 2018;123:1-6.
    PubMed     Text format     Abstract available


    August 2018
  22. DICKHOFF C, Dahele M
    In Regard to Robinson et al: Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018 Aug 16. pii: S0169-5002(18)30527.
    PubMed     Text format    


  23. CHOUAID C, Danson S, Andreas S, Siakpere O, et al
    Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
    Lung Cancer. 2018 Aug 10. pii: S0169-5002(18)30503.
    PubMed     Text format     Abstract available


  24. LEE YG, Lee JH, Kim SH, Kim YJ, et al
    Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
    Lung Cancer. 2018;122:88-93.
    PubMed     Text format     Abstract available


  25. HO JC, Leung CC
    Management of co-existent tuberculosis and lung cancer.
    Lung Cancer. 2018;122:83-87.
    PubMed     Text format     Abstract available


  26. GUIBERT N, Tsukada H, Hwang DH, Chambers E, et al
    Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
    Lung Cancer. 2018;122:72-75.
    PubMed     Text format     Abstract available


  27. CHAFT JE, Dagogo-Jack I, Santini FC, Eng J, et al
    Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
    Lung Cancer. 2018;122:67-71.
    PubMed     Text format     Abstract available


  28. DENG W, Xu T, Wang Y, Xu Y, et al
    Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
    Lung Cancer. 2018;122:60-66.
    PubMed     Text format     Abstract available


  29. OSUOHA CA, Callahan KE, Ponce CP, Pinheiro PS, et al
    Disparities in lung cancer survival and receipt of surgical treatment.
    Lung Cancer. 2018;122:54-59.
    PubMed     Text format     Abstract available


  30. SI X, Zhang L, Wang H, Zhang X, et al
    Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:32-37.
    PubMed     Text format     Abstract available


  31. TRIPHURIDET N, Vidhyarkorn S, Worakitsitisatorn A, Sricharunrat T, et al
    Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Lung Cancer. 2018;122:243-248.
    PubMed     Text format     Abstract available


  32. LEE JS, Lee KH, Cho EK, Kim DW, et al
    Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lung Cancer. 2018;122:234-242.
    PubMed     Text format     Abstract available


  33. ZAHEDI A, Phandthong R, Chaili A, Remark G, et al
    Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes.
    Lung Cancer. 2018;122:224-233.
    PubMed     Text format     Abstract available


  34. AHMED T, Vial MR, Ost D, Stewart J, et al
    Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.
    Lung Cancer. 2018;122:220-223.
    PubMed     Text format     Abstract available


  35. TAKAHASHI N, Tsuji K, Tamiya H, Shinohara T, et al
    Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
    Lung Cancer. 2018;122:22-24.
    PubMed     Text format     Abstract available


  36. GOYAL G, Kommalapati A, Bartley AC, Gunderson TM, et al
    Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
    Lung Cancer. 2018;122:214-219.
    PubMed     Text format     Abstract available


  37. ROBINSON LA, Tanvetyanon T, Grubbs D, Antonia S, et al
    Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018;122:206-213.
    PubMed     Text format     Abstract available


  38. IZUMI H, Yamasaki A, Takeda K, Kodani M, et al
    Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:200-205.
    PubMed     Text format     Abstract available


  39. MATYS T, Drury R, David S, Rassl DM, et al
    Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
    Lung Cancer. 2018;122:195-199.
    PubMed     Text format     Abstract available


  40. YAP S, Goldsbury D, Yap ML, Yuill S, et al
    Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study.
    Lung Cancer. 2018;122:171-179.
    PubMed     Text format     Abstract available


  41. BRUSTUGUN OT, Gronberg BH, Fjellbirkeland L, Helbekkmo N, et al
    Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.
    Lung Cancer. 2018;122:138-145.
    PubMed     Text format     Abstract available


  42. MILLARES L, Barreiro E, Cortes R, Martinez-Romero A, et al
    Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
    Lung Cancer. 2018;122:124-130.
    PubMed     Text format     Abstract available


  43. INOUE T, Katoh N, Ito YM, Kimura T, et al
    Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study.
    Lung Cancer. 2018;122:107-112.
    PubMed     Text format     Abstract available


  44. SEBASTIAN M, Ryden A, Walding A, Papadimitrakopoulou V, et al
    Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:100-106.
    PubMed     Text format     Abstract available


  45. ZHAO B, Zhang W, Yu D, Xu J, et al
    Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018;122:10-21.
    PubMed     Text format     Abstract available


  46. WANG H, Zhang L, Hu P, Zheng X, et al
    Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.
    Lung Cancer. 2018;122:1-6.
    PubMed     Text format     Abstract available


    July 2018
  47. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].
    Lung Cancer. 2018 Jul 13. pii: S0169-5002(18)30468.
    PubMed     Text format    


  48. VERONESI G, Zulueta JJ, Maisonneuve P, Henschke C, et al
    At last we can go ahead with low-dose CT screening for lung cancer in Europe.
    Lung Cancer. 2018 Jul 10. pii: S0169-5002(18)30470.
    PubMed     Text format    


  49. KUIJPERS CCHJ, Hendriks LEL, Derks JL, Dingemans AC, et al
    Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Lung Cancer. 2018;121:76-81.
    PubMed     Text format     Abstract available


  50. TOMONAGA Y, Ten Haaf K, Frauenfelder T, Kohler M, et al
    Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
    Lung Cancer. 2018;121:61-69.
    PubMed     Text format     Abstract available


  51. XIE F, Zhang Y, Mao X, Zheng X, et al
    Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naive advanced non-squamous non-small cell lung cancer patients.
    Lung Cancer. 2018;121:54-60.
    PubMed     Text format     Abstract available


  52. NIE K, Zhang Z, Zhang C, Geng C, et al
    Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Lung Cancer. 2018;121:5-11.
    PubMed     Text format     Abstract available


  53. KOBAYASHI H, Naito T, Omae K, Omori S, et al
    ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
    Lung Cancer. 2018;121:48-53.
    PubMed     Text format     Abstract available


  54. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2018;121:37-40.
    PubMed     Text format     Abstract available


  55. TOPKAN E, Selek U, Ozdemir Y, Yildirim BA, et al
    Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;121:30-36.
    PubMed     Text format     Abstract available


  56. YANG M, Tong X, Xu X, Zheng E, et al
    Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.
    Lung Cancer. 2018;121:1-4.
    PubMed     Text format     Abstract available


    June 2018
  57. ANDREAS S, Chouaid C, Danson S, Siakpere O, et al
    Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Lung Cancer. 2018 Jun 9. pii: S0169-5002(18)30416.
    PubMed     Text format     Abstract available


  58. KIMURA S, Harada T, Ijichi K, Tanaka K, et al
    Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.
    Lung Cancer. 2018;120:98-107.
    PubMed     Text format     Abstract available


  59. LIMWATTANANON C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T, et al
    Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Lung Cancer. 2018;120:91-97.
    PubMed     Text format     Abstract available


  60. ROBIN TP, Jones BL, Amini A, Koshy M, et al
    Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
    Lung Cancer. 2018;120:88-90.
    PubMed     Text format     Abstract available


  61. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
    Lung Cancer. 2018;120:75-81.
    PubMed     Text format     Abstract available


  62. RECK M, Garassino MC, Imbimbo M, Shepherd FA, et al
    Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
    Lung Cancer. 2018;120:62-69.
    PubMed     Text format     Abstract available


  63. LEE CC, Zheng H, Soon YY, Foo LL, et al
    Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy.
    Lung Cancer. 2018;120:54-59.
    PubMed     Text format     Abstract available


  64. FORSTER M, Hackshaw A, De Pas T, Cobo M, et al
    A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
    Lung Cancer. 2018;120:27-33.
    PubMed     Text format     Abstract available


  65. BRADBURY PA, Morris DG, Nicholas G, Tu D, et al
    Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Lung Cancer. 2018;120:142-148.
    PubMed     Text format     Abstract available


  66. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Lung Cancer. 2018;120:137-141.
    PubMed     Text format     Abstract available


  67. DU M, Thompson J, Fisher H, Zhang P, et al
    Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Lung Cancer. 2018;120:113-121.
    PubMed     Text format     Abstract available


  68. GUIBERT N, Delaunay M, Lusque A, Boubekeur N, et al
    PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Lung Cancer. 2018;120:108-112.
    PubMed     Text format     Abstract available


  69. REITER MJ, Nemesure A, Madu E, Reagan L, et al
    Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.
    Lung Cancer. 2018;120:1-6.
    PubMed     Text format     Abstract available


    May 2018
  70. BRAILLON A
    Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Lung Cancer. 2018 May 21. pii: S0169-5002(18)30382.
    PubMed     Text format    


  71. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
    Lung Cancer. 2018 May 3. pii: S0169-5002(18)30350.
    PubMed     Text format    


  72. D'SILVA A, Gardiner PA, Boyle T, Bebb DG, et al
    Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.
    Lung Cancer. 2018;119:78-84.
    PubMed     Text format     Abstract available


  73. RAEZ LE, Cardona AF, Santos ES, Catoe H, et al
    The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.
    Lung Cancer. 2018;119:7-13.
    PubMed     Text format     Abstract available


  74. YANG SM, Chen LW, Wang HJ, Chen LR, et al
    Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification.
    Lung Cancer. 2018;119:56-63.
    PubMed     Text format     Abstract available


  75. CHRISTOPOULOS P, Schneider MA, Bozorgmehr F, Kuon J, et al
    Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
    Lung Cancer. 2018;119:48-55.
    PubMed     Text format     Abstract available


  76. MODING EJ, Diehn M, Wakelee HA
    Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Lung Cancer. 2018;119:42-47.
    PubMed     Text format     Abstract available


  77. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Lung Cancer. 2018;119:14-20.
    PubMed     Text format     Abstract available


  78. BORGHAEI H, Yim YM, Guerin A, Pivneva I, et al
    Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Lung Cancer. 2018;119:112-119.
    PubMed     Text format     Abstract available


  79. BURUDPAKDEE C, Wong W, Seetasith A, Corvino FA, et al
    Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;119:103-111.
    PubMed     Text format     Abstract available


  80. KANG YK, Song YS, Cho S, Jheon S, et al
    Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
    Lung Cancer. 2018;119:1-6.
    PubMed     Text format     Abstract available


    April 2018
  81. TSAO MS, Yoon JY
    The eighth TNM classification for lung cancer-What is next?
    Lung Cancer. 2018 Apr 25. pii: S0169-5002(18)30346.
    PubMed     Text format    


  82. YEN CC, Su HC, Chu CY, Lai SJ, et al
    Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
    Lung Cancer. 2018 Apr 17. pii: S0169-5002(18)30342.
    PubMed     Text format    


  83. LIAO WY, Ho CC, Tsai TH, Chen KY, et al
    Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Lung Cancer. 2018;118:90-96.
    PubMed     Text format     Abstract available


  84. HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
    Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Lung Cancer. 2018;118:6-12.
    PubMed     Text format     Abstract available


  85. SONG Z, Cheng G, Xu C, Wang W, et al
    Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:57-61.
    PubMed     Text format     Abstract available


  86. LEE JW, Choi JS, Lyu J, Lee SM, et al
    Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
    Lung Cancer. 2018;118:41-47.
    PubMed     Text format     Abstract available


  87. BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
    Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Lung Cancer. 2018;118:20-26.
    PubMed     Text format     Abstract available


  88. HELFRICH BA, Gao D, Bunn PA Jr
    Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Lung Cancer. 2018;118:148-154.
    PubMed     Text format     Abstract available


  89. HUDSON A, Chan C, Woolf D, McWilliam A, et al
    Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
    Lung Cancer. 2018;118:139-147.
    PubMed     Text format     Abstract available


  90. SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
    The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
    Lung Cancer. 2018;118:134-138.
    PubMed     Text format     Abstract available


  91. IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
    High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:13-19.
    PubMed     Text format     Abstract available


  92. COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
    Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Lung Cancer. 2018;118:119-127.
    PubMed     Text format     Abstract available


  93. FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
    MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Lung Cancer. 2018;118:111-118.
    PubMed     Text format     Abstract available


  94. LIU Y, Li Y, Ou Q, Wu X, et al
    Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Lung Cancer. 2018;118:1-5.
    PubMed     Text format     Abstract available


    March 2018
  95. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
    Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
    PubMed     Text format    


  96. LI J, Wang Z, Groen HJM, Zhao J, et al
    Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
    PubMed     Text format    


  97. GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
    Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Lung Cancer. 2018;117:44-49.
    PubMed     Text format     Abstract available


  98. SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
    Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Lung Cancer. 2018;117:38-43.
    PubMed     Text format     Abstract available


  99. SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
    A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
    Lung Cancer. 2018;117:32-37.
    PubMed     Text format     Abstract available


  100. ZHANG B, Xu J, Zhang X, Gu P, et al
    Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Lung Cancer. 2018;117:27-31.
    PubMed     Text format     Abstract available


  101. YANG W, Qian F, Teng J, Wang H, et al
    Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
    Lung Cancer. 2018;117:20-26.
    PubMed     Text format     Abstract available


  102. OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
    Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Lung Cancer. 2018;117:14-19.
    PubMed     Text format     Abstract available


  103. ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
    High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Lung Cancer. 2018;117:1-6.
    PubMed     Text format     Abstract available


    February 2018
  104. ODA K, Kato K, Nakamura M, Jotatsu T, et al
    Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
    PubMed     Text format    


  105. BARUA S, Fang P, Sharma A, Fujimoto J, et al
    Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
    Lung Cancer. 2018 Feb 3. pii: S0169-5002(18)30236.
    PubMed     Text format     Abstract available


  106. VANDERLAAN PA, Rangachari D, Majid A, Parikh MS, et al
    Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    Lung Cancer. 2018;116:90-95.
    PubMed     Text format     Abstract available


  107. CHENG CC, Chou KF, Wu CW, Su NW, et al
    EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:80-89.
    PubMed     Text format     Abstract available


  108. ARAN V, Masson Domingues P, Carvalho de Macedo F, Moreira de Sousa CA, et al
    A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
    Lung Cancer. 2018;116:7-14.
    PubMed     Text format     Abstract available


  109. GAUVAIN C, Vauleon E, Chouaid C, Lerhun E, et al
    Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Lung Cancer. 2018;116:62-66.
    PubMed     Text format     Abstract available


  110. DRIESSEN EJM, Schulkes KJG, Dingemans AC, van Loon JGM, et al
    Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;116:55-61.
    PubMed     Text format     Abstract available


  111. CUI S, Cheng Z, Qin W, Jiang L, et al
    Exosomes as a liquid biopsy for lung cancer.
    Lung Cancer. 2018;116:46-54.
    PubMed     Text format     Abstract available


  112. PARK KS, Moon YW, Raffeld M, Lee DH, et al
    High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Lung Cancer. 2018;116:38-45.
    PubMed     Text format     Abstract available


  113. ARNEY J, Helm A, Crook T, Braun UK, et al
    Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
    Lung Cancer. 2018;116:25-29.
    PubMed     Text format     Abstract available


  114. MCLEER-FLORIN A, Duruisseaux M, Pinsolle J, Dubourd S, et al
    ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:15-24.
    PubMed     Text format     Abstract available


  115. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].
    Lung Cancer. 2018 Feb 1. pii: S0169-5002(17)30564.
    PubMed     Text format    


    January 2018
  116. GOROSPE L, Arrieta P, Ajuria-Illarramendi O, Barbolla-Diaz I, et al
    Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer.
    Lung Cancer. 2018 Jan 17. pii: S0169-5002(18)30018.
    PubMed     Text format    


  117. KHAN SA, Pruitt SL, Xuan L, Makris U, et al
    How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
    Lung Cancer. 2018;115:97-102.
    PubMed     Text format     Abstract available


  118. LEE J, Kim HK, Park BJ, Cho JH, et al
    Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lung Cancer. 2018;115:89-96.
    PubMed     Text format     Abstract available


  119. TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
    Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Lung Cancer. 2018;115:84-88.
    PubMed     Text format     Abstract available


  120. YANG CJ, Gu L, Shah SA, Yerokun BA, et al
    Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
    Lung Cancer. 2018;115:75-83.
    PubMed     Text format     Abstract available


  121. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2018;115:71-74.
    PubMed     Text format     Abstract available


  122. HUANG HC, Su WJ, Chiang CL, Feng JY, et al
    The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2018;115:64-70.
    PubMed     Text format     Abstract available


  123. TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
    Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Lung Cancer. 2018;115:49-55.
    PubMed     Text format     Abstract available


  124. THAWANI R, McLane M, Beig N, Ghose S, et al
    Radiomics and radiogenomics in lung cancer: A review for the clinician.
    Lung Cancer. 2018;115:34-41.
    PubMed     Text format     Abstract available


  125. ISAKA M, Kojima H, Takahashi S, Omae K, et al
    Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Lung Cancer. 2018;115:28-33.
    PubMed     Text format     Abstract available


  126. EVISON M, Edwards T, Balata H, Tempowski A, et al
    Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
    Lung Cancer. 2018;115:127-130.
    PubMed     Text format     Abstract available


  127. SOO RA, Lim SM, Syn NL, Teng R, et al
    Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Lung Cancer. 2018;115:12-20.
    PubMed     Text format     Abstract available


  128. TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
    Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Lung Cancer. 2018;115:116-120.
    PubMed     Text format     Abstract available


  129. LIU X, Jiang T, Li W, Li X, et al
    Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
    Lung Cancer. 2018;115:109-115.
    PubMed     Text format     Abstract available


  130. NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
    A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer. 2018;115:103-108.
    PubMed     Text format     Abstract available


    December 2017
  131. LIU E, Guha A, Jia K, Ayers AM, et al
    Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
    Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
    PubMed     Text format    


  132. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
    Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
    PubMed     Text format    


  133. GROSSI F, Genova C, Rijavec E, Barletta G, et al
    Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Lung Cancer. 2017 Dec 13. pii: S0169-5002(17)30614.
    PubMed     Text format     Abstract available


  134. TU HY, Ke EE, Yang JJ, Sun YL, et al
    A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;114:96-102.
    PubMed     Text format     Abstract available


  135. TIAN HX, Zhang XC, Yang JJ, Guo WB, et al
    Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
    Lung Cancer. 2017;114:90-95.
    PubMed     Text format     Abstract available


  136. SHEN J, Ye Y, Chang DW, Huang M, et al
    Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Lung Cancer. 2017;114:70-78.
    PubMed     Text format     Abstract available


  137. CHALMERS A, Jensen L, Akerley W
    Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
    Lung Cancer. 2017;114:68-69.
    PubMed     Text format     Abstract available


  138. ZHU Y, Li T, Chen G, Yan G, et al
    Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p.
    Lung Cancer. 2017;114:6-11.
    PubMed     Text format     Abstract available


  139. KEUSTERS WR, de Weger VA, Hovels A, Schellens JHM, et al
    Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Lung Cancer. 2017;114:56-61.
    PubMed     Text format     Abstract available


  140. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2017;114:44-49.
    PubMed     Text format     Abstract available


  141. WANG X, Leader JK, Wang R, Wilson D, et al
    Vasculature surrounding a nodule: A novel lung cancer biomarker.
    Lung Cancer. 2017;114:38-43.
    PubMed     Text format     Abstract available


  142. ZANON M, Pacini GS, de Souza VVS, Marchiori E, et al
    Early detection of lung cancer using ultra-low-dose computed tomography in coronary CT angiography scans among patients with suspected coronary heart disease.
    Lung Cancer. 2017;114:1-5.
    PubMed     Text format     Abstract available


  143. HAN L, Lee CK, Pang H, Chan HT, et al
    Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
    Lung Cancer. 2017;114:79-89.
    PubMed     Text format     Abstract available


  144. YAMAUCHI Y, Safi S, Muley T, Warth A, et al
    C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Lung Cancer. 2017;114:62-67.
    PubMed     Text format     Abstract available


  145. KUIJVENHOVEN JC, Crombag L, Breen DP, van den Berk I, et al
    Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients.
    Lung Cancer. 2017;114:50-55.
    PubMed     Text format     Abstract available


  146. WANG L, Guo Q, Yu W, Qiao L, et al
    Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
    Lung Cancer. 2017;114:31-37.
    PubMed     Text format     Abstract available


  147. MATSUMURA Y, Suzuki H, Ohira T, Shiono S, et al
    Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Lung Cancer. 2017;114:23-30.
    PubMed     Text format     Abstract available


  148. FOY V, Schenk MW, Baker K, Gomes F, et al
    Targeting DNA damage in SCLC.
    Lung Cancer. 2017;114:12-22.
    PubMed     Text format     Abstract available


    November 2017
  149. DUDNIK E, Moskovitz M, Daher S, Shamai S, et al
    Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Lung Cancer. 2017 Nov 23. pii: S0169-5002(17)30582.
    PubMed     Text format     Abstract available


  150. SCHOUTEN RD, Muller M, de Gooijer CJ, Baas P, et al
    Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Lung Cancer. 2017 Nov 17. pii: S0169-5002(17)30569.
    PubMed     Text format    


  151. GOROSPE L, Garcia-Latorre R, Ajuria-Illarramendi O, Arrieta P, et al
    Lipoid pneumonia mimicking multifocal lung cancer in a patient with a remote laryngectomy and a recently diagnosed lung cancer: PET/CT findings.
    Lung Cancer. 2017 Nov 7. pii: S0169-5002(17)30560.
    PubMed     Text format    


  152. GOROSPE L, Sanchez-Monforte JC, Cabanas-Montero J, Arrieta P, et al
    Incidental retroperitoneal malignant solitary fibrous tumor detected at lung cancer screening with low-dose thoracic CT.
    Lung Cancer. 2017 Nov 6. pii: S0169-5002(17)30561.
    PubMed     Text format    


  153. AHMED Z, Grover P, Kennedy KF, Masood A, et al
    Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis.
    Lung Cancer. 2017;113:85-87.
    PubMed     Text format    


  154. SPIGEL DR, Rubin MS, Gian VG, Shipley DL, et al
    Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung Cancer. 2017;113:79-84.
    PubMed     Text format     Abstract available


  155. KAWANO Y, Iwama E, Tsuchihashi K, Shibahara D, et al
    CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Lung Cancer. 2017;113:72-78.
    PubMed     Text format     Abstract available


  156. KATO T, Jin CS, Ujiie H, Lee D, et al
    Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
    Lung Cancer. 2017;113:59-68.
    PubMed     Text format     Abstract available


  157. HORN L, Gettinger S, Camidge DR, Smit EF, et al
    Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Lung Cancer. 2017;113:51-58.
    PubMed     Text format     Abstract available


  158. HEUVELMANS MA, Walter JE, Peters RB, Bock GH, et al
    Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
    Lung Cancer. 2017;113:45-50.
    PubMed     Text format     Abstract available


  159. HOCHMAIR MJ, Schwab S, Burghuber OC, Krenbek D, et al
    Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
    Lung Cancer. 2017;113:4-6.
    PubMed     Text format     Abstract available


  160. CORRALES-RODRIGUEZ L, Arrieta O, Mas L, Baez-Saldana R, et al
    An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
    Lung Cancer. 2017;113:30-36.
    PubMed     Text format     Abstract available


  161. LIU C, Cui H, Gu D, Zhang M, et al
    Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.
    Lung Cancer. 2017;113:18-29.
    PubMed     Text format     Abstract available


  162. BOUAZZA YB, Chiairi I, El Kharbouchi O, De Backer L, et al
    Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review.
    Lung Cancer. 2017;113:140-151.
    PubMed     Text format     Abstract available


  163. SANTONI-RUGIU E, Grauslund M, Melchior LC, Costa JC, et al
    Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Lung Cancer. 2017;113:14-17.
    PubMed     Text format     Abstract available


  164. ICHIKAWA T, Saruwatari K, Mimaki S, Sugano M, et al
    Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
    Lung Cancer. 2017;113:134-139.
    PubMed     Text format     Abstract available


  165. SCHMIDT LH, Stucke-Ring J, Brand C, Schliemann C, et al
    CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Lung Cancer. 2017;113:121-127.
    PubMed     Text format     Abstract available


  166. TALBOT T, Dangoor A, Shah R, Naik J, et al
    The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
    Lung Cancer. 2017;113:115-120.
    PubMed     Text format     Abstract available


  167. LEE CK, Kim S, Lee JS, Lee JE, et al
    Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lung Cancer. 2017;113:106-114.
    PubMed     Text format     Abstract available


  168. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods.
    Lung Cancer. 2017;113:1-3.
    PubMed     Text format     Abstract available


    October 2017
  169. SAWA K, Koh Y, Kawaguchi T, Kambayashi S, et al
    PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Lung Cancer. 2017;112:96-101.
    PubMed     Text format     Abstract available


  170. SCHVARTSMAN G, Peng SA, Bis G, Lee JJ, et al
    Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:90-95.
    PubMed     Text format     Abstract available


  171. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
    Lung Cancer. 2017;112:81-89.
    PubMed     Text format     Abstract available


  172. HE Y, Rozeboom L, Rivard CJ, Ellison K, et al
    MHC class II expression in lung cancer.
    Lung Cancer. 2017;112:75-80.
    PubMed     Text format     Abstract available


  173. ROS-MAZURCZYK M, Jelonek K, Marczyk M, Binczyk F, et al
    Serum lipid profile discriminates patients with early lung cancer from healthy controls.
    Lung Cancer. 2017;112:69-74.
    PubMed     Text format     Abstract available


  174. FACCHINETTI F, Bluthgen MV, Tergemina-Clain G, Faivre L, et al
    LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Lung Cancer. 2017;112:62-68.
    PubMed     Text format     Abstract available


  175. TOMIZAWA K, Shimizu S, Ohara S, Fujino T, et al
    Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.
    Lung Cancer. 2017;112:57-61.
    PubMed     Text format     Abstract available


  176. LEFRESNE S, Olson R, Cashman R, Kostuik P, et al
    Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic.
    Lung Cancer. 2017;112:35-40.
    PubMed     Text format     Abstract available


  177. NISHIE K, Yamamoto S, Nagata C, Koizumi T, et al
    Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
    Lung Cancer. 2017;112:25-34.
    PubMed     Text format     Abstract available


  178. KUYAMA S, Ochi N, Bessho A, Hotta K, et al
    A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Lung Cancer. 2017;112:188-194.
    PubMed     Text format     Abstract available


  179. RECK M, Paz-Ares L, Bidoli P, Cappuzzo F, et al
    Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Lung Cancer. 2017;112:181-187.
    PubMed     Text format     Abstract available


  180. QIN N, Wang C, Zhu M, Lu Q, et al
    Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.
    Lung Cancer. 2017;112:169-175.
    PubMed     Text format     Abstract available


  181. LARA JD, Brunson A, Riess JW, Kelly K, et al
    Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
    Lung Cancer. 2017;112:165-168.
    PubMed     Text format     Abstract available


  182. VINOD SK, Chandra A, Berthelsen A, Descallar J, et al
    Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Lung Cancer. 2017;112:16-24.
    PubMed     Text format     Abstract available


  183. JACOBSEN MM, Silverstein SC, Quinn M, Waterston LB, et al
    Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review.
    Lung Cancer. 2017;112:156-164.
    PubMed     Text format     Abstract available


  184. EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
    Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study.
    Lung Cancer. 2017;112:140-155.
    PubMed     Text format     Abstract available


  185. KWINT M, Walraven I, Burgers S, Hartemink K, et al
    Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Lung Cancer. 2017;112:134-139.
    PubMed     Text format     Abstract available


  186. PAZ-ARES LG, Perol M, Ciuleanu TE, Kowalyszyn RD, et al
    Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:126-133.
    PubMed     Text format     Abstract available


  187. AGGARWAL C, Wang X, Ranganathan A, Torigian D, et al
    Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Lung Cancer. 2017;112:118-125.
    PubMed     Text format     Abstract available


  188. SNOECKX A, Dendooven A, Carp L, Desbuquoit D, et al
    Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities.
    Lung Cancer. 2017;112:109-117.
    PubMed     Text format     Abstract available


  189. MEZQUITA L, Charrier M, Faivre L, Dupraz L, et al
    Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
    Lung Cancer. 2017;112:10-15.
    PubMed     Text format     Abstract available


    September 2017
  190. ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
    Lung cancer in renal transplant recipients: A case-control study.
    Lung Cancer. 2017;111:96-100.
    PubMed     Text format     Abstract available


  191. MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
    Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
    Lung Cancer. 2017;111:88-95.
    PubMed     Text format     Abstract available


  192. LIM SM, Chang H, Cha YJ, Liang S, et al
    Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lung Cancer. 2017;111:79-83.
    PubMed     Text format     Abstract available


  193. MOON SM, Lee DG, Hwang NY, Ahn S, et al
    Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
    Lung Cancer. 2017;111:69-74.
    PubMed     Text format     Abstract available


  194. TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
    Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Lung Cancer. 2017;111:65-68.
    PubMed     Text format     Abstract available


  195. CAPELAN M, Roda D, Geuna E, Rihawi K, et al
    Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Lung Cancer. 2017;111:6-11.
    PubMed     Text format     Abstract available


  196. CALIFANO R, Greystoke A, Lal R, Thompson J, et al
    Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2017;111:51-58.
    PubMed     Text format     Abstract available


  197. SHEN L, Niu X, Jian H, Xu Y, et al
    Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;111:43-50.
    PubMed     Text format     Abstract available


  198. MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
    Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Lung Cancer. 2017;111:38-42.
    PubMed     Text format     Abstract available


  199. GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
    Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
    Lung Cancer. 2017;111:30-37.
    PubMed     Text format     Abstract available


  200. LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;111:23-29.
    PubMed     Text format     Abstract available


  201. HATA A, Katakami N, Nanjo S, Okuda C, et al
    Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;111:182-189.
    PubMed     Text format     Abstract available


  202. DIEM S, Schmid S, Krapf M, Flatz L, et al
    Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Lung Cancer. 2017;111:176-181.
    PubMed     Text format     Abstract available


  203. SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
    Lung Cancer. 2017;111:164-175.
    PubMed     Text format     Abstract available


  204. RUELLE L, Bentea G, Sideris S, El Koulali M, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
    Lung Cancer. 2017;111:150-163.
    PubMed     Text format     Abstract available


  205. WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
    TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
    Lung Cancer. 2017;111:15-22.
    PubMed     Text format     Abstract available


  206. YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
    Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
    Lung Cancer. 2017;111:131-134.
    PubMed     Text format     Abstract available


  207. GAGLIASSO M, Migliaretti G, Ardissone F
    Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
    Lung Cancer. 2017;111:124-130.
    PubMed     Text format     Abstract available


  208. TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
    Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
    Lung Cancer. 2017;111:101-107.
    PubMed     Text format     Abstract available


  209. FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Lung Cancer. 2017;111:1-5.
    PubMed     Text format     Abstract available


    August 2017
  210. VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
    PubMed     Text format     Abstract available


  211. CHENG YW, Chiou HL, Chen JT, Chou MC, et al
    Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
    Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
    PubMed     Text format    


  212. LIAO BC, Lin CC, Lee JH, Yang JC, et al
    Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Lung Cancer. 2017;110:7-13.
    PubMed     Text format     Abstract available


  213. KIM EY, Kim A, Kim SK, Chang YS, et al
    MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Lung Cancer. 2017;110:63-67.
    PubMed     Text format     Abstract available


  214. KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
    De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
    Lung Cancer. 2017;110:53-55.
    PubMed     Text format     Abstract available


  215. TAO MH, Dai Q, Chen S, Freudenheim JL, et al
    Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
    Lung Cancer. 2017;110:42-47.
    PubMed     Text format     Abstract available


  216. KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
    Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Lung Cancer. 2017;110:35-41.
    PubMed     Text format     Abstract available


  217. SANDS J, Li Q, Hornberger J
    Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Lung Cancer. 2017;110:19-25.
    PubMed     Text format     Abstract available


  218. DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
    Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Lung Cancer. 2017;110:14-18.
    PubMed     Text format     Abstract available


    July 2017
  219. LIU E, Guha A, Bertino E, Franco V, et al
    Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
    Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
    PubMed     Text format    


  220. SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
    Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
    PubMed     Text format     Abstract available


  221. TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
    Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
    Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
    PubMed     Text format    


  222. YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
    Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Lung Cancer. 2017;109:89-91.
    PubMed     Text format     Abstract available


  223. WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
    Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Lung Cancer. 2017;109:78-88.
    PubMed     Text format     Abstract available


  224. LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
    The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lung Cancer. 2017;109:68-73.
    PubMed     Text format     Abstract available


  225. ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
    Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Lung Cancer. 2017;109:62-67.
    PubMed     Text format     Abstract available


  226. FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
    Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
    Lung Cancer. 2017;109:52-57.
    PubMed     Text format     Abstract available


  227. GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
    Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
    Lung Cancer. 2017;109:36-41.
    PubMed     Text format     Abstract available


  228. ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
    Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
    Lung Cancer. 2017;109:28-35.
    PubMed     Text format     Abstract available


  229. O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
    Uncommon EGFR mutations in advanced non-small cell lung cancer.
    Lung Cancer. 2017;109:137-144.
    PubMed     Text format     Abstract available


  230. WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
    Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
    Lung Cancer. 2017;109:117-123.
    PubMed     Text format     Abstract available


  231. SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
    Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Lung Cancer. 2017;109:1-8.
    PubMed     Text format     Abstract available


  232. DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
    Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Lung Cancer. 2017;109:92-100.
    PubMed     Text format     Abstract available


  233. DEARDEN S, Brown H, Jenkins S, Thress KS, et al
    EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Lung Cancer. 2017;109:9-13.
    PubMed     Text format     Abstract available


  234. RASKIN J, Masrori P, Cant A, Snoeckx A, et al
    Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Lung Cancer. 2017;109:74-77.
    PubMed     Text format     Abstract available


  235. ITO J, Fujimoto D, Nakamura A, Nagano T, et al
    Aprepitant for refractory nivolumab-induced pruritus.
    Lung Cancer. 2017;109:58-61.
    PubMed     Text format     Abstract available


  236. YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
    Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Lung Cancer. 2017;109:45-51.
    PubMed     Text format     Abstract available


  237. UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
    Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Lung Cancer. 2017;109:42-44.
    PubMed     Text format     Abstract available


  238. ZHANG L, Li S, Choi YL, Lee J, et al
    Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Lung Cancer. 2017;109:21-27.
    PubMed     Text format     Abstract available


  239. BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
    Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
    Lung Cancer. 2017;109:14-20.
    PubMed     Text format     Abstract available


  240. HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
    The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
    Lung Cancer. 2017;109:128-136.
    PubMed     Text format     Abstract available


  241. ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
    Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Lung Cancer. 2017;109:124-127.
    PubMed     Text format     Abstract available


  242. ZHANG L, Li J, Hu J, Li D, et al
    Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Lung Cancer. 2017;109:109-116.
    PubMed     Text format     Abstract available


  243. GADGEEL S, Goss G, Soria JC, Felip E, et al
    Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Lung Cancer. 2017;109:101-108.
    PubMed     Text format     Abstract available


    June 2017
  244. GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
    Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
    Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
    PubMed     Text format    


  245. ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
    Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Lung Cancer. 2017;108:96-102.
    PubMed     Text format     Abstract available


  246. GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
    Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
    Lung Cancer. 2017;108:90-95.
    PubMed     Text format     Abstract available


  247. IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
    LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Lung Cancer. 2017;108:83-89.
    PubMed     Text format     Abstract available


  248. HIDAKA N, Iwama E, Kubo N, Harada T, et al
    Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;108:75-82.
    PubMed     Text format     Abstract available


  249. GION M, Remon J, Caramella C, Soria JC, et al
    Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Lung Cancer. 2017;108:72-74.
    PubMed     Text format     Abstract available


  250. NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
    Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Lung Cancer. 2017;108:66-71.
    PubMed     Text format     Abstract available


  251. MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
    Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
    Lung Cancer. 2017;108:62-65.
    PubMed     Text format     Abstract available


  252. YU XQ, Luo Q, Kahn C, Grogan P, et al
    Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
    Lung Cancer. 2017;108:55-61.
    PubMed     Text format     Abstract available


  253. CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
    EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
    Lung Cancer. 2017;108:38-44.
    PubMed     Text format     Abstract available


  254. SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
    Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Lung Cancer. 2017;108:232-237.
    PubMed     Text format     Abstract available


  255. KOSHY M, Malik R, Spiotto M, Mahmood U, et al
    Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Lung Cancer. 2017;108:222-227.
    PubMed     Text format     Abstract available


  256. RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
    Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Lung Cancer. 2017;108:217-221.
    PubMed     Text format     Abstract available


  257. WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
    A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Lung Cancer. 2017;108:212-216.
    PubMed     Text format     Abstract available


  258. DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Lung Cancer. 2017;108:198-204.
    PubMed     Text format     Abstract available


  259. YANG SC, Lai WW, Lin CC, Su WC, et al
    Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Lung Cancer. 2017;108:183-191.
    PubMed     Text format     Abstract available


  260. HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
    A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Lung Cancer. 2017;108:173-182.
    PubMed     Text format     Abstract available


  261. MORAN T, Palmero R, Provencio M, Insa A, et al
    A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Lung Cancer. 2017;108:154-160.
    PubMed     Text format     Abstract available


  262. MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
    A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Lung Cancer. 2017;108:15-21.
    PubMed     Text format     Abstract available


  263. PATEL MI, McKinley M, Cheng I, Haile R, et al
    Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
    Lung Cancer. 2017;108:140-149.
    PubMed     Text format     Abstract available


  264. KRON F, Kostenko A, Scheffler M, Muller D, et al
    Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
    Lung Cancer. 2017;108:134-139.
    PubMed     Text format     Abstract available


  265. KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
    Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Lung Cancer. 2017;108:126-133.
    PubMed     Text format     Abstract available


  266. PATEL SH, Rimner A, Foster A, Zhang Z, et al
    Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2017;108:109-114.
    PubMed     Text format     Abstract available


  267. MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
    Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Lung Cancer. 2017;108:103-108.
    PubMed     Text format     Abstract available


    April 2017
  268. SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
    Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
    PubMed     Text format    


  269. TANAKA N, Toyooka S, Soh J, Kubo T, et al
    Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
    PubMed     Text format    


  270. EDWARDS T, Balata H, Foden P, Crosbie P, et al
    Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
    Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
    PubMed     Text format    


  271. METRO G, Tazza M, Matocci R, Chiari R, et al
    Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Lung Cancer. 2017;106:58-66.
    PubMed     Text format     Abstract available


  272. BASLER L, Kroeze SG, Guckenberger M
    SBRT for oligoprogressive oncogene addicted NSCLC.
    Lung Cancer. 2017;106:50-57.
    PubMed     Text format     Abstract available


  273. VANDERLAAN PA, Rangachari D, Mockus SM, Spotlow V, et al
    Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    Lung Cancer. 2017;106:17-21.
    PubMed     Text format     Abstract available


  274. KWON D, Koh J, Kim S, Go H, et al
    MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Lung Cancer. 2017;106:131-137.
    PubMed     Text format     Abstract available


  275. HONG SW, Park NS, Noh MH, Shim JA, et al
    Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Lung Cancer. 2017;106:115-124.
    PubMed     Text format     Abstract available


    March 2017
  276. LI H, Yang T, Ning Q, Shang D, et al
    MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
    Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
    PubMed     Text format     Abstract available


  277. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed     Text format    


    February 2017
  278. HIDA T, Hamasaki M, Matsumoto S, Sato A, et al
    Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Lung Cancer. 2017;104:98-105.
    PubMed     Text format     Abstract available


  279. SAKAGUCHI H, Ishida H, Nitanda H, Yamazaki N, et al
    Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
    Lung Cancer. 2017;104:70-74.
    PubMed     Text format     Abstract available


  280. TAKADA K, Okamoto T, Toyokawa G, Kozuma Y, et al
    The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Lung Cancer. 2017;104:7-15.
    PubMed     Text format     Abstract available


  281. LAURIE SA, Hao D, Leighl NB, Goffin J, et al
    A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Lung Cancer. 2017;104:65-69.
    PubMed     Text format     Abstract available


  282. WU YL, Saijo N, Thongprasert S, Yang JC, et al
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Lung Cancer. 2017;104:119-125.
    PubMed     Text format     Abstract available


    January 2017
  283. TO KK, Tong WS, Fu LW
    Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    Lung Cancer. 2017;103:58-65.
    PubMed     Text format     Abstract available


  284. TSIM S, Stobo DB, Alexander L, Kelly C, et al
    The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
    Lung Cancer. 2017;103:38-43.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: